| Document |
Document Title |
|
WO/2011/127585A1 |
The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related...
|
|
WO/2011/118599A1 |
Provided are a filler for affinity chromatography which is highly tolerant to alkalis, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler wherein a protein represented by general formula (1) is ...
|
|
WO/2011/109298A2 |
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL...
|
|
WO/2011/102342A1 |
Disclosed are an antibody-immobilized carrier capable of use in antibody screening, a method of producing the antibody-immobilized carrier, and use of said antibody-immobilized carrier. The antibody-immobilized carrier is provided indepe...
|
|
WO/2011/091286A1 |
The present invention relates to surprisingly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian cancer. In particular, the present invention is based on...
|
|
WO/2011/003085A9 |
The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
|
|
WO/2011/089903A1 |
The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented ...
|
|
WO/2011/083735A1 |
Provided are a composite material, wherein a metal is carried in a pore of a protein crystal, and a method for producing the same.
|
|
WO/2011/085231A2 |
Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of t...
|
|
WO/2011/084705A2 |
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include l-cyano-4-pyrrolidino...
|
|
WO/2011/060528A1 |
Reagents, kits, uses and methods useful for example fo decreasing nonspecific adsorption of biomolecules at the surface of a solid support are disclosed. Such reagents and methods, which are based on short heteropeptides, may be used to ...
|
|
WO/2011/063127A1 |
The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of m...
|
|
WO/2011/058315A2 |
The invention relates to a glucose binding protein comprising amino acid mutations relative to the wild type sequence at the following positions: (i) H 152, (ii) A213; and (iii) L238 wherein the mutation at position H 152 is H152C. The i...
|
|
WO/2011/055682A1 |
Disclosed are: a multilayer transparent light-receiving element which can be easily produced, while having extremely high optical response speed; and a high-performance electronic device which uses the multilayer transparent light-receiv...
|
|
WO/2011/041897A1 |
The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a compostion capable of transporting an agent...
|
|
WO/2011/041906A1 |
The present invention relates to a method for covalently attaching a compound to a stainless steel, tin, iron, or titanium substrate, by contacting exposed surface(s) of the substrate with a synthetic pilin peptide containing a disulfide...
|
|
WO/2011/040823A1 |
The present invention relates to novel synthetic myostatin antagonists, comprising a synthetic mature myostatin peptide, wherein the peptide comprises at least two cysteine residues at positions 281 and 282 which are forced to bond and f...
|
|
WO/2011/037896A2 |
The invention provides methods for the PEGylation of an N-terminal cysteine of a polypeptide such that the thiol group of the cysteine is unreacted in the final PEGylated polypeptide. In one embodiment, the invention comprises a method o...
|
|
WO/2011/030682A1 |
Disclosed is a construct comprising a virus coat-constituting protein, which is usable as a drug delivery carrier applicable to various drugs. Specifically disclosed is a construct coated with a virus coat-constituting protein which is c...
|
|
WO/2011/026351A1 |
A cyanovirin N (CVN) mutant, its PEG modified derivative and their uses in preparing drugs. The said cyanovirin N mutant is composed of sequence A and sequence B: sequence A is a linker peptide with hydrophilicity and flexibility, sequen...
|
|
WO/2011/022824A1 |
A method is provided for optical protein patterning by photobleaching using a microscope having an objective and a camera port, the objective and the camera port defining respective focal planes. The method comprises positioning a substr...
|
|
WO/2010/101526A9 |
Described is a new standalone diguanylate cyclase polypeptide having a GGDEF motif and a mutated I-site that does not bind c-di-GMP. We demonstrate that the production yield of c-di-GMP and analogues was significantly increased by mutati...
|
|
WO/2011/025158A2 |
The present invention relates to a coacervate including the adhesive protein of a mussel and an ionic polymer, and particularly, to a coacervate prepared by mixing the adhesive protein of a mussel and an ionic polymer, and to a novel use...
|
|
WO/2011/017101A2 |
This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membr...
|
|
WO/2011/015530A2 |
The invention relates to a process for the deposition of a metal oxide, such as titanium dioxide, as a thin layer on a substrate, by using particular biopolymers, in particular hydrophobin. The process for the deposition of a metal oxide...
|
|
WO/2011/017514A1 |
The present invention relates, at least in part, to improved methods of protein purification. In particular, the present invention relates, at least in part, to methods for purifying an Fc region containing protein from a composition com...
|
|
WO/2011/010964A1 |
Techniques for differentiating isobaric species are described. An isobaric species may be substituted with a tagging species identified using mass spectrometry. The isobaric species may be a subunit of a first polymer having a defined se...
|
|
WO/2010/150375A1 |
Disclosed is a modified biotin-conjugated protein which is characterized by having any one substitution selected from the group consisting of items 1) to 6) shown below in a protein which comprises the amino acid sequence depicted in SEQ...
|
|
WO/2010/142035A1 |
The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor ...
|
|
WO/2010/143983A1 |
Methods for the diagnosis of infection with Treponema palladium using a peptide-spacer-lipid construct are disclosed, where the spacer covalently links the peptide to the lipid. The peptide is a peptide comprising the sequence AlaSerGlyA...
|
|
WO/2010/142850A1 |
In the field of drug or nutrient administration novel particles and formulations thereof are provided. Said particles each have a core comprising active agent and at least partial coating comprising proteins, selected from hydrophobins. ...
|
|
WO/2010/138486A1 |
The present invention provides substrates useful for culturing cells under low serum or serum free conditions. The substrates are useful for conducting cell-based assays where there is interference from serum proteins. Methods are also p...
|
|
WO/2010/135800A1 |
A silicon substrate for use in biosensing applications is provided, having a protective layer made of a hydrophobic dendrimer monolayer linked to a hydrophilic layer presenting biomolecule probes. The hydrophobic monolayer inhibits oxida...
|
|
WO/2010/136617A1 |
The present invention relates to an amphiphilic polymeric conjugate that comprises general formula I, to the synthesis thereof and to the use of same as a drug for treating bacterial infections.
|
|
WO/2010/138522A2 |
The present invention relates to embedding live or dead microorganisms and/or bioactive materials in a protective dry formulation matrix, wherein the formulation includes the bioactive microorganism or material, a formulation stabilizer ...
|
|
WO/2010/134084A1 |
The present invention relates to a method of purifying human growth hormone from a mixture containing at least one related impurity; and a purified growth hormone with purity of at least 85%.
|
|
WO/2010/019725A9 |
Engineered proteins are used in the assembly of two-dimensional and three-dimensional nanostructure assemblies, based on systematic design and production of protein node structures that can be interconnected, for example, with streptavid...
|
|
WO/2010/126115A1 |
Disclosed is a method for screening an antibody which is to be co-crystallized with a membrane protein. Specifically disclosed is a liposome-membrane protein complex which is used for screening an antibody to be co-crystallized with a me...
|
|
WO/2010/121352A1 |
A combination therapy is described comprising the CYP-metabolized compound Simvastatin and the growth hormone releasing factor (GRF) analogue (hexenoyl trans-3)hGRF(l-44)NH2 (tesamorelin), for the treatment of HIV- associated lipodystrop...
|
|
WO/2010/121559A1 |
The invention provides a novel exendin variant and the exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating d...
|
|
WO/2010/121351A1 |
A combination therapy is described comprising the protease inhibitor Ritonavir and the growth hormone releasing factor (GRF) analogue (hexenoyl trans-3)hGRF(1-44)NH2 (TH9507), for the treatment of HIV- associated lipodystrophy. Human gro...
|
|
WO/2010/118985A1 |
The present application relates to an affinity material useful in antibody purification.
|
|
WO/2010/115835A2 |
The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules ...
|
|
WO/2010/114031A1 |
Disclosed are: a method for detecting a substance in a biological sample; a carrier for use in the method; and a kit. The method comprises the following steps 1) to 4): 1) providing a carrier having a biotin-binding protein bound thereto...
|
|
WO/2010/109284A1 |
In some aspects, the present invention provides ultrashort lipopeptides which feature ß -amino acids or ß-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositi...
|
|
WO/2010/101694A1 |
The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolate...
|
|
WO/2010/101886A1 |
The present invention relates to methods and compositions for the treatment of cancer. The methods and compositions involve the use of the Salmonella effector protein AvrA, as well as variants or fragments thereof, or encoding nucleic ac...
|
|
WO/2010/099515A2 |
The present invention creates an immunologically protected/enhanced space in vivo in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within...
|
|
WO/2010/091122A1 |
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and...
|
|
WO/2010/087781A1 |
A process is described for producing a loaded complex comprising a polyelectrolyte complex bound to a biologically active peptide. In this process, a solution of a polyanion is combined with a solution of a polycation to form the polyele...
|
